Dr. McCullough and his team at The Wellness Company are exploring whether two well-known antiparasitic drugs, ivermectin and mebendazole, might be repurposed to help fight cancer. This piece walks through why those drugs drew attention, what laboratory findings suggest so far, and why careful clinical research is essential before anyone changes treatment plans.
Dr. McCullough’s group is part of a broader trend of researchers looking to repurpose existing medications for new uses. Repurposing can shave years off development time because safety profiles are already established, and that practical appeal is one reason antiparasitics caught investigators’ eyes. The Wellness Company is focusing on whether combining ivermectin with mebendazole produces effects worth taking into formal clinical trials.
Ivermectin is best known as an antiparasitic used in humans and animals, but laboratory studies have flagged multiple potential anticancer actions. In cell cultures and some animal models, ivermectin has been shown to interfere with cellular pathways that support tumor growth and survival. Those early findings are intriguing but far from proof that anything similar will occur in people with cancer.
Mebendazole is another antiparasitic that acts on microtubules, the protein structures that help cells divide. Because cancer depends on rapid cell division, disrupting microtubules is a proven anticancer strategy for several chemotherapy drugs, and mebendazole has produced anti-tumor activity in preclinical experiments. Like ivermectin, most of the evidence for mebendazole comes from lab work and animal studies rather than controlled human trials.
The idea of combining the two drugs rests on complementary mechanisms: one agent may alter cellular signaling while the other affects structural elements of division, potentially creating added stress on tumor cells. Some researchers think that hitting cancer from multiple angles can reduce the chance of resistance and target diverse tumor populations. However, synergy observed in dishes or mice does not automatically translate into human benefit, and combinations can also amplify toxicity.
At present, the evidence base is mostly preclinical and anecdotal, with case reports and small observational experiences occasionally mentioned in public discussions. That kind of information can generate hypotheses but cannot establish safety or efficacy for cancer treatment. Randomized, controlled clinical trials remain the gold standard and are necessary to determine whether any signal seen in the lab has real-world value for patients.
Safety is a key consideration because approved doses for parasitic infections may differ from what investigators test against tumors. Both ivermectin and mebendazole have known side effect profiles when used at standard doses, but higher or prolonged dosing in oncology could present new risks. Any use outside an approved indication should occur only within properly supervised clinical trials and with full informed consent.
Moving a repurposed drug combination into mainstream oncology requires more than promising lab data; it needs protocol development, funding, regulatory review, and peer-reviewed publication of trial results. Ethical oversight and carefully chosen endpoints help ensure trials produce useful information and protect participants. If The Wellness Company advances to formal studies, those steps will determine whether the initial curiosity becomes a credible treatment option.
The research underway is an example of creative science driven by urgent need and practical thinking about existing medicines. Observers should watch for peer-reviewed trial reports rather than media summaries or informal claims. If the work progresses, it will be the clinical data that decides whether ivermectin and mebendazole have a role in cancer care, not preliminary laboratory excitement.
